Table 1.

Neurologically active drugs.

Disease	Drug category	References
AD	FDA accepted	Donepezil, galantamine, rivastigmine, memantine, and donezil + memantine (Caselli et al., 2017)
	Natural phytochemicals	Triptolide extract (Li et al., 2016) and punicalagin (Kim et al., 2017)
	Cannabinoid agonists	WIN, 2-AG, and methanandamide (Aguirre-Rueda et al., 2015; Gajardo-Gomez et al., 2017)
	Endogenous antioxidant factors	Pelargonidine (Sohanaki et al., 2016), Bambusae concretio Salicea (Jeong et al., 2005), monascin (Shi et al., 2016)
	Exogenous antioxidant compounds	Resveratrol (Wang et al., 2016), tocotrienol (Ibrahim et al., 2017), anthocyanins (Rehman et al., 2017), epicatechin (Cuevas et al., 2009), and 3H-1,2-dithiole-3-thione (Wang et al., 2017)
	Stimulators of the GLT1 expression	Penicillin, cephalosporin, ampicillin, estrogen, riluzole, and insulin (Frizzo et al., 2004; Brann et al., 2007; Ji et al., 2011)
	Activators of the GLT1 translation	Pyridazine and LDN/OSU-0212320 (Colton et al., 2010; Xing et al., 2011)
	GABA receptor antagonists	(Yuan and Shan, 2014)
Epilepsy	AED	Valproic acid, lamotrigine, phenobarbital, gabapentin, felbamate, and topiramate (French and Gazzola, 2011)
	Anticancer drug	Rapamycin (Huang et al., 2010; Kim and Lee, 2019)
	Allosteric potentiators of glutamine synthetase, regulators of AQP4 trafficking, interleukin 1 antagonists, and agonists or allosteric potentiators of TNFR2	(Wetherington et al., 2008) (Crunelli et al., 2015)
Ischemic stroke	Stimulators of the GLT1 expression	Ceftriaxone (Ouyang et al., 2007; Verma et al., 2010), carnosine (Shen et al., 2010), and tamoxifen (Lee et al., 2009)
	Inhibitors of p53 activity	MicroRNA-29a (Ouyang et al., 2013; Ouyang et al., 2014)
	Stimulators of angiogenesis	Ecdysterone (Luo et al., 2011) and omega-3 polyunsaturated fatty acids (Wang et al., 2014)